A study by France’s Pasteur Institute found people who had received two doses of Pfizer saw a three-fold reduction in their antibodies against the B. 1.617 variant. The co-author of the research said the findings show that ‘this variant has acquired partial resistance to antibodies’ The Pfizer vaccine is slightly less effective but appears to still protect against the more transmissible Covid-19
“The situation was different with the AstraZeneca vaccine, which induced particularly low levels of antibodies neutralising” the Indian variant, the study said. Patients who had Covid-19 within the past year and people vaccinated with two doses of Pfizer retained enough antibodies to be protected against the Indian variant, but three to six times less antibodies than against the UK variant, Schwartz said. The study shows that “this variant has acquired partial resistance to antibodies,” Schwartz said. Since first emerging in late 2019 in China, the SARS-CoV-2 virus that causes Covid-19 has developed several variants, usually named for the places where it first appeared including the so-called South Africa and UK strains. The variant first detected in India appears to be much more transmissible than earlier variations. It has now been officially recorded in 53 territories, according to a World Health Organization report. To try to curb its spread, France and Germany have reintroduced tighter rules on arrivals from affected countries, including Britain.
Preprint available at bioRxiv (May 27, 2021):